During the last session, Arbutus Biopharma Corp (NASDAQ:ABUS)’s traded shares were 1.11 million, with the beta value of the company hitting 1.29. At the end of the trading day, the stock’s price was $3.29, reflecting an intraday loss of -0.90% or -$0.03. The 52-week high for the ABUS share is $4.72, that puts it down -43.47 from that peak though still a striking 17.93% gain since the share price plummeted to a 52-week low of $2.70. The company’s market capitalization is $629.97M, and the average trade volume was 1.04 million shares over the past three months.
Arbutus Biopharma Corp (ABUS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.50. ABUS has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.
Arbutus Biopharma Corp (NASDAQ:ABUS) trade information
Arbutus Biopharma Corp (ABUS) registered a -0.90% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.90% in intraday trading to $3.29, hitting a weekly high. The stock’s 5-day price performance is -7.32%, and it has moved by 9.48% in 30 days. Based on these gigs, the overall price performance for the year is 21.40%.
The consensus price target of analysts on Wall Street is $8.5, which implies an increase of 61.29% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8.5 and $8.5 respectively. As a result, ABUS is trading at a discount of -158.36% off the target high and -158.36% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 33.46%. While earnings are projected to return 43.68% in 2025, the next five years will return 49.14% per annum.
ABUS Dividends
Arbutus Biopharma Corp is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 12.87 million shares, is of WHITEFORT CAPITAL MANAGEMENT, LP’s that is approximately 6.8432% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $39.76 million.
Also, the Mutual Funds coming in first place with the largest holdings of Arbutus Biopharma Corp (ABUS) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Morgan Stanley Insight Fund . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 4.87 shares. This amounts to just over 2.54 percent of the company’s overall shares, with a $16.03 million market value. The same data shows that the other fund manager holds slightly less at 4.24, or about 2.22% of the stock, which is worth about $13.97 million.
